Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Henlius' Hetronifly (serplulimab) gains European Commission approval for squamous non-small cell lung cancer first-line treatment
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, PD-1 inhibitor, combination therapy - Read more

Komodo Health, Alnylam Pharmaceuticals expand strategic partnership to scale Marmot AI analytics platform enterprise-wide
Strategic partnership, AI/ML, data analytics, RNAi therapeutics, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Epicrispr Biotechnologies’ (EPI-321) DUX4 silencer boosts muscle in facioscapulohumeral muscular dystrophy patients in Ph1/2 trial
Gene therapy, neurological, epigenetic silencing, facioscapulohumeral muscular dystrophy, DUX4 target - Read more

Abbisko Therapeutics' ABSK061 and ABSK043 (FGFR2/3 and PD-L1 inhibitors) show 90% objective response rate in Ph2 gastric cancer trial
Small molecule, cancer, FGFR inhibitor, gastric cancer, PD-L1, combination therapy - Read more

Definium Therapeutics raises $805M upsized public offering, advancing psychiatric and neurological disorder treatments
Neurological, psychiatric disorders, small molecule, clinical-stage - Read more

LigaChem Biosciences Inc. raises 500B KRW (323K) via convertible bonds, advancing ADC pipeline and next-generation platforms
Antibody-drug conjugate, oncology, clinical-stage, platform technology - Read more

Artivila Biopharma raises $12.8M Series A, advancing AI-driven drug discovery platform
AI-driven, drug discovery, clinical-stage, platform technology - Read more

Optimeos Life Sciences receives undisclosed investment from Hatch BioFund, expanding nanoparticle drug delivery operations
Nanoparticle platform, drug delivery, rare disease, gene therapy, RNA/DNA therapeutics - Read more

Nuvation Bio prices upsized $250M convertible notes offering, debt repayment and corporate purposes
Oncology, small molecule, clinical-stage - Read more

Bayer wins Supreme Court ruling overturning $1.25M Roundup cancer verdict, shares surge 19%
Oncology, competitive, revenue impact - Read more

FDA accepts Replimune's RP1 resubmission for advanced melanoma, sets early August decision after two prior rejections
Oncolytic virus, cancer, immunotherapy, melanoma, accelerated approval - Read more

Moderna maps three-wave R&D roadmap at Science Day, targeting 2028 break-even with 7+ products
mRNA vaccine, oncology, rare disease, respiratory disease, strategic, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Biogen cuts staff, halts most Apellis research programs one month after $5.6B acquisition
Small molecule, rare disease, major transaction, cost reduction - Read more

Amgen's Tavneos loses EU endorsement over data integrity concerns ahead of FDA hearing
Small molecule, rare disease, regulatory, competitive - Read more

Sanofi faces formal EU antitrust probe over campaign allegedly disparaging CSL Seqirus' flu vaccine Fluad
Vaccine, infectious disease, regulatory, competitive, antitrust - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here